Sign In
Buy BLUE
$4.97
+0 (+0%)
At Close: Aug 29, 2025
Stock Down 98% From Peak, Bluebird Bio Could Run Out Of Cash
09:33am, Friday, 22'nd Apr 2022
Investors recently raised bearish bets that this cash burning biotech will burn through what remains. Shares have fallen 24% in the two weeks since it announced cost cuts.
Where Will Bluebird Bio Be in 1 Year?
03:15pm, Sunday, 17'th Apr 2022 The Motley Fool
It's going to be an interesting next 12 months for the biotech.
Where Will Bluebird Bio Be in 1 Year?
11:15am, Sunday, 17'th Apr 2022
It's going to be an interesting next 12 months for the biotech.
Is Bluebird Bio a Buy?
03:30pm, Friday, 15'th Apr 2022 The Motley Fool
The expected upcoming catalysts might not be all that the company needs.
Is Bluebird Bio a Buy?
11:30am, Friday, 15'th Apr 2022
The expected upcoming catalysts might not be all that the company needs.
Layoffs at Bluebird Bio Highlight the Current Struggles of Biotech Picks
06:57am, Friday, 08'th Apr 2022
Cash will be king in biotech picks like BLUE stock as governments slow approvals and reimbursements of new gene therapies. The post Layoffs at Bluebird Bio Highlight the Current Struggles of Biotech P
bluebird (BLUE) Undertakes Restructuring Moves to Curb Cash Burn
04:36pm, Wednesday, 06'th Apr 2022 Zacks Investment Research
bluebird (BLUE) intends to reduce the existing workforce by nearly 30% to reduce 2022 operating expenses by 35-40%. This is likely to generate cost savings of $160 million over two years.
bluebird (BLUE) Undertakes Restructuring Moves to Curb Cash Burn
02:18pm, Wednesday, 06'th Apr 2022
bluebird (BLUE) intends to reduce the existing workforce by nearly 30% to reduce 2022 operating expenses by 35-40%. This is likely to generate cost savings of $160 million over two years.
Benzinga's Top Ratings Upgrades, Downgrades For April 6, 2022
02:16pm, Wednesday, 06'th Apr 2022 Benzinga
Upgrades
According to Morgan Stanley, the prior rating for Royalty Pharma PLC (NASDAQ:RPRX) was changed from Equal-Weight to Overweight. In the fourth quarter, Royalty Pharma showed an EPS of $0.80, c
Expert Ratings For bluebird bio
01:28pm, Wednesday, 06'th Apr 2022 Benzinga
Within the last quarter, bluebird bio (NASDAQ:BLUE) has observed the following analyst ratings:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
0
0
3
2
0
Last 30
10 Biggest Price Target Changes For Wednesday
11:14am, Wednesday, 06'th Apr 2022 Benzinga
Raymond James reduced the price target on Intercontinental Exchange, Inc. (NYSE: ICE) from $161 to $157. Intercontinental Exchange shares rose 0.2% to $130.79 in pre-market trading.
Loop Capital cut
Precigen (PGEN) Up on FDA Fast Track Tag for CAR-T Candidate
12:58pm, Tuesday, 05'th Apr 2022 Zacks Investment Research
Precigen (PGEN) is developing CAR T therapy candidate, PRGN-3006 UltraCAR-T, for treating acute myeloid leukemia in a phase I study. The FDA grants Fast Track designation.
Gene-therapy biotech Bluebird Bio is set to lay off 30% of the company after warning it could struggle to survive through 2022
09:52am, Tuesday, 05'th Apr 2022
Insider identified Bluebird Bio last month as one of 13 biotechs in a dangerous financial position.
5 Stocks That Wall Street Hates This Week
09:33am, Friday, 11'th Mar 2022
Wall Street analysts are constantly releasing and updating reports on stocks across their respective coverage universes.
Why Bluebird Bio Stock Is Sinking This Week
10:01pm, Thursday, 10'th Mar 2022 The Motley Fool
The unexpected departure of its CFO and an ominous note of caution rattled investors.
